1
|
Sturm L, van Elst LT, Fiebich B, Wolkewitz M, Hornig T. Intra-day variations of blood reelin levels in healthy individuals. Arch Med Sci 2019; 16:118-123. [PMID: 32051714 PMCID: PMC6963140 DOI: 10.5114/aoms.2020.91288] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Accepted: 08/07/2017] [Indexed: 12/02/2022] Open
Abstract
INTRODUCTION Reelin (RELN) is an extracellular glycoprotein best known to be crucial for neuronal migration during the embryonic period and regulation of synaptic plasticity in the adult brain, with recent studies pointing to reelin playing an important part in the organization of peripheral organs as well. Abnormalities in RELN function are associated with a variety of medical conditions in human beings. These alterations partly also reflect in RELN's blood levels, which gives it a clinical relevance as a potential biomarker. Requirement for a possible clinical use is a profound understanding of RELN's physiology. We hypothesized blood RELN levels could underlie time-dependent variations and therefore examined individuals' serum reelin concentrations in the course of one day. MATERIAL AND METHODS We obtained blood samples from healthy individuals (n = 10) at several times of measurement over a time period of 24 h. We subsequently determined the respective serum RELN concentrations utilizing an enzyme-linked immunosorbent assay and tested for intra- and interindividual variations in serum RELN concentrations over time. RESULTS All tested individuals' serum RELN levels displayed significant intraindividual variations in the course of 24 h. Test subjects' reelin day profiles showed substantial divergence among each other. CONCLUSIONS Our findings point to short-term fluctuations in blood RELN levels being part of physiological RELN homeostasis. This is of special interest with regard to a potential clinical use of RELN as a biomarker.
Collapse
Affiliation(s)
- Lukas Sturm
- Department of Psychiatry, University Hospital Freiburg, Freiburg, Germany
| | | | - Bernd Fiebich
- Department of Psychiatry, University Hospital Freiburg, Freiburg, Germany
| | - Martin Wolkewitz
- Department of Medical Biometrics and Medical Informatics, University of Freiburg, Freiburg, Germany
| | - Tobias Hornig
- Department of Psychiatry, University Hospital Freiburg, Freiburg, Germany
| |
Collapse
|
2
|
Kolaka R, Chotwiwatthanakun C, Chutabhakdikul N. Fetal exposure to high levels of maternal glucocorticoids alters reelin signaling in the prefrontal cortex of rat pups. Int J Dev Neurosci 2019; 78:185-190. [PMID: 31014819 DOI: 10.1016/j.ijdevneu.2019.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 04/06/2019] [Accepted: 04/10/2019] [Indexed: 10/27/2022] Open
Abstract
Maternal stress (MS) is associated with various neuropsychiatric disorders and cognitive impairment in the offspring. However, it is unclear how early life stress alters the pup's brain development and how it contributes to the pathology of neuropsychiatric disorders later in life. Reelin is a large extracellular matrix glycoprotein that plays essential roles in early brain development such as neural migration, synaptic development, and maturation. Dysregulation of reelin and its signaling proteins is associated with the emergence of neuropsychiatric disorders in adulthood. This study examined the effect of repeated maternal Carbenoxolone (CBX) injection during late gestation on reelin signaling in the prefrontal cortex (PFC) of rat pups. CBX is a selective 11β-HSD2 enzyme inhibitor that promotes the direct transfer of maternal corticosteroids (CORT) to the fetus. Therefore, treatment with CBX can mimic the animal model of early life exposure to high levels of maternal stress hormone. In this study, pregnant rats were injected daily with either saline or CBX during gestation day (GD) 14-21, and the levels of reelin and its signaling proteins were examined in the PFC of rat pups at different postnatal age from P0-P21. The main result of this study is the repeated maternal CBX injections during GD14-21 acutely increase reln mRNA and protein expression in the PFC of rat pups at birth (P0) and follow by a significant decrease during P7-P14. The treatment also causes long term decreases in the amount of VLDLR and Dab1 which are the downstream signaling proteins for the reelin pathway, at least until P21. Our results indicated that fetal exposure to high levels of maternal CORT interferes with reelin signaling which might have profound effects on cortical development associated with neuropsychiatric disorders later in life.
Collapse
Affiliation(s)
- Ratirat Kolaka
- Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand
| | | | - Nuanchan Chutabhakdikul
- Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand
| |
Collapse
|
3
|
Khialeeva E, Carpenter EM. Nonneuronal roles for the reelin signaling pathway. Dev Dyn 2016; 246:217-226. [PMID: 27739126 DOI: 10.1002/dvdy.24462] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 10/09/2016] [Accepted: 10/10/2016] [Indexed: 12/21/2022] Open
Abstract
The reelin signaling pathway has been established as an important regulator of cell migration during development of the central nervous system, and disruptions in reelin signaling alter the positioning of many types of neurons. Reelin is a large extracellular matrix glycoprotein and governs cell migration through activation of multiple intracellular signaling events by means of the receptors ApoE receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR), and the intracellular adaptor protein Disabled-1 (Dab1). Earlier studies reported expression of reelin in nonneuronal tissues, but the functions of this signaling pathway outside of the nervous system have not been studied until recently. A large body of evidence now suggests that reelin functions during development and disease of multiple nonneuronal tissues. This review addresses recent advances in the field of nonneuronal reelin signaling. Developmental Dynamics 246:217-226, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Elvira Khialeeva
- Molecular Biology Interdepartmental Program, University of California Los Angeles, Los Angeles, California
| | - Ellen M Carpenter
- Department of Psychiatry and Biobehavioral Science, University of California Los Angeles School of Medicine, Los Angeles, California
| |
Collapse
|
4
|
Mata A, Urrea L, Vilches S, Llorens F, Thüne K, Espinosa JC, Andréoletti O, Sevillano AM, Torres JM, Requena JR, Zerr I, Ferrer I, Gavín R, Del Río JA. Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies. Mol Neurobiol 2016; 54:6412-6425. [PMID: 27726110 DOI: 10.1007/s12035-016-0177-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 09/28/2016] [Indexed: 12/22/2022]
Abstract
Reelin is an extracellular glycoprotein involved in key cellular processes in developing and adult nervous system, including regulation of neuronal migration, synapse formation, and plasticity. Most of these roles are mediated by the intracellular phosphorylation of disabled-1 (Dab1), an intracellular adaptor molecule, in turn mediated by binding Reelin to its receptors. Altered expression and glycosylation patterns of Reelin in cerebrospinal and cortical extracts have been reported in Alzheimer's disease. However, putative changes in Reelin are not described in natural prionopathies or experimental models of prion infection or toxicity. With this is mind, in the present study, we determined that Reelin protein and mRNA levels increased in CJD human samples and in mouse models of human prion disease in contrast to murine models of prion infection. However, changes in Reelin expression appeared only at late terminal stages of the disease, which prevent their use as an efficient diagnostic biomarker. In addition, increased Reelin in CJD and in in vitro models does not correlate with Dab1 phosphorylation, indicating failure in its intracellular signaling. Overall, these findings widen our understanding of the putative changes of Reelin in neurodegeneration.
Collapse
Affiliation(s)
- Agata Mata
- Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15-21, 08028, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Laura Urrea
- Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15-21, 08028, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Silvia Vilches
- Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15-21, 08028, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Franc Llorens
- Department of Neurology, German Center for Neurodegenerative Diseases - DZNE, Universitätsmedizin Göttingen, Bonn, Germany
| | - Katrin Thüne
- Department of Neurology, German Center for Neurodegenerative Diseases - DZNE, Universitätsmedizin Göttingen, Bonn, Germany
| | - Juan-Carlos Espinosa
- Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Valdeolmos, Spain
| | - Olivier Andréoletti
- UMR INRA ENVT 1225, Interactions Hôtes Agents Pathogènes, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, 31076, Toulouse, France
| | - Alejandro M Sevillano
- CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, 15782, Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Juan María Torres
- Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Valdeolmos, Spain
| | - Jesús Rodríguez Requena
- CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, 15782, Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Inga Zerr
- Department of Neurology, German Center for Neurodegenerative Diseases - DZNE, Universitätsmedizin Göttingen, Bonn, Germany
| | - Isidro Ferrer
- Institut de Neuropatologia, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Rosalina Gavín
- Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15-21, 08028, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - José Antonio Del Río
- Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15-21, 08028, Barcelona, Spain.
- Department of Cell Biology, Physiology and Immunology, Universitat de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
- Institute of Neuroscience, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
5
|
Rodríguez-Carballo E, Gámez B, Méndez-Lucas A, Sánchez-Freutrie M, Zorzano A, Bartrons R, Alcántara S, Perales JC, Ventura F. p38α function in osteoblasts influences adipose tissue homeostasis. FASEB J 2014; 29:1414-25. [PMID: 25550462 DOI: 10.1096/fj.14-261891] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Accepted: 11/24/2014] [Indexed: 12/19/2022]
Abstract
The skeleton acts as an endocrine organ that regulates energy metabolism and calcium and phosphorous homeostasis through the secretion of osteocalcin (Oc) and fibroblast growth factor 23 (FGF23). However, evidence suggests that osteoblasts secrete additional unknown factors that contribute to the endocrine function of bone. To search for these additional factors, we generated mice with a conditional osteoblast-specific deletion of p38α MAPK known to display profound defects in bone homeostasis. Herein, we show that impaired osteoblast function is associated with a strong decrease in body weight and adiposity (P < 0.01). The differences in adiposity were not associated with diminished caloric intake, but rather reflected 20% increased energy expenditure and the up-regulation of uncoupling protein-1 (Ucp1) in white adipose tissue (WAT) and brown adipose tissue (BAT) (P < 0.05). These alterations in lipid metabolism and energy expenditure were correlated with a decrease in the blood levels of neuropeptide Y (NPY) (40% lower) rather than changes in the serum levels of insulin, Oc, or FGF23. Among all Npy-expressing tissues, only bone and primary osteoblasts showed a decline in Npy expression (P < 0.01). Moreover, the intraperitoneal administration of recombinant NPY partially restored the WAT weight and adipocyte size of p38α-deficient mice (P < 0.05). Altogether, these results further suggest that, in addition to Oc, other bone-derived signals affect WAT and energy expenditure contributing to the regulation of energy metabolism.
Collapse
Affiliation(s)
- Edgardo Rodríguez-Carballo
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Beatriz Gámez
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Andrés Méndez-Lucas
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Manuela Sánchez-Freutrie
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Antonio Zorzano
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Ramon Bartrons
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Soledad Alcántara
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - José Carlos Perales
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| | - Francesc Ventura
- *Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Ma Y, Li X, Fu J, Li Y, Gao L, Yang L, Zhang P, Shen J, Wang H. Acetylcholine affects osteocytic MLO-Y4 cells via acetylcholine receptors. Mol Cell Endocrinol 2014; 384:155-64. [PMID: 24508663 DOI: 10.1016/j.mce.2014.01.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Revised: 01/21/2014] [Accepted: 01/28/2014] [Indexed: 02/06/2023]
Abstract
The identification of the neuronal control of bone remodeling has become one of the many significant recent advances in bone biology. Cholinergic activity has recently been shown to favor bone mass accrual by complex cellular regulatory networks. Here, we identified the gene expression of the muscarinic and nicotinic acetylcholine receptors (m- and nAChRs) in mice tibia tissue and in osteocytic MLO-Y4 cells. Acetylcholine, which is a classical neurotransmitter and an osteo-neuromediator, not only influences the mRNA expression of the AChR subunits but also significantly induces the proliferation and viability of osteocytes. Moreover, acetylcholine treatment caused the reciprocal regulation of RANKL and OPG mRNA expression, which resulted in a significant increase in the mRNA ratio of RANKL:OPG in osteocytes via acetylcholine receptors. The expression of neuropeptide Y and reelin, which are two neurogenic markers, was also modulated by acetylcholine via m- and nAChRs in MLO-Y4 cells. These results indicated that osteocytic acetylcholine receptors might be a new valuable mediator for cell functions and even for bone remodeling.
Collapse
Affiliation(s)
- Yuanyuan Ma
- Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China
| | - Xianxian Li
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China; Department of Prosthodontics, West China College of Stomatology, Sichuan University, Chengdu 610041, China
| | - Jing Fu
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China; Department of Prosthodontics, West China College of Stomatology, Sichuan University, Chengdu 610041, China
| | - Yue Li
- Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 400016, China; The Affiliated Hospital of Stomatology, Chongqing Medical University, Chongqing 400016, China
| | - Li Gao
- Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China
| | - Ling Yang
- Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China
| | - Ping Zhang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
| | - Jiefei Shen
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China; Department of Prosthodontics, West China College of Stomatology, Sichuan University, Chengdu 610041, China
| | - Hang Wang
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China; Department of Prosthodontics, West China College of Stomatology, Sichuan University, Chengdu 610041, China.
| |
Collapse
|
7
|
Lim J, Lee SH, Cho S, Lee IS, Kang BY, Choi HJ. 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells. Mol Cells 2013; 36:340-6. [PMID: 24046186 PMCID: PMC3887984 DOI: 10.1007/s10059-013-0123-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 07/22/2013] [Accepted: 07/25/2013] [Indexed: 12/23/2022] Open
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcriptional regulator for the protection of cells against oxidative and xenobiotic stresses. Recent studies have demonstrated that high constitutive expression of Nrf2 is observed in many types of cancer cells showing resistance to anti-cancer drugs, suggesting that the suppression of overexpressed Nrf2 could be an attractive therapeutic strategy to overcome cancer drug resistance. In the present study, we aimed to find small molecule compounds that enhance the sensitivity of tumor cells to cisplatin induced cytotoxicity by suppressing Nrf2-mediated defense mechanism. A549 lung cancer cells were shown to be more resistant to the anti-cancer drug cisplatin than HEK293 cells, with higher Nrf2 signaling activity; constitutively high amounts of Nrf2-downstream target proteins were observed in A549 cells. Among the three chalcone derivatives 4-methoxy-chalcone (4-MC), hesperidin methylchalcone, and neohesperidin dihydrochalcone, 4-MC was found to suppress transcriptional activity of Nrf2 in A549 cells but to activate it in HEK293 cells. 4-MC was also shown to down-regulate expression of Nrf2 and the downstream phase II detoxifying enzyme NQO1 in A549 cells. The PI3K/Akt pathway was found to be involved in the 4-MC-induced inhibition of Nrf2/ARE activity in A549 cells. This inhibition of Nrf2 signaling results in the accelerated generation of reactive oxygen species and exacerbation of cytotoxicity in cisplatin-treated A549 cells. Taken together, these results suggest that the small molecule compound 4-MC could be used to enhance the sensitivity of tumor cells to the therapeutic effect of cisplatin through the regulation of Nrf2/ARE signaling.
Collapse
Affiliation(s)
- Juhee Lim
- College of Pharmacy, CHA University, Seongnam 463-836, Korea
| | | | | | | | | | - Hyun Jin Choi
- College of Pharmacy, CHA University, Seongnam 463-836, Korea
| |
Collapse
|
8
|
Polman JAE, de Kloet ER, Datson NA. Two populations of glucocorticoid receptor-binding sites in the male rat hippocampal genome. Endocrinology 2013; 154:1832-44. [PMID: 23525215 DOI: 10.1210/en.2012-2187] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In the present study, genomic binding sites of glucocorticoid receptors (GR) were identified in vivo in the rat hippocampus applying chromatin immunoprecipitation followed by next-generation sequencing. We identified 2470 significant GR-binding sites (GBS) and were able to confirm GR binding to a random selection of these GBS covering a wide range of P values. Analysis of the genomic distribution of the significant GBS revealed a high prevalence of intragenic GBS. Gene ontology clusters involved in neuronal plasticity and other essential neuronal processes were overrepresented among the genes harboring a GBS or located in the vicinity of a GBS. Male adrenalectomized rats were challenged with increasing doses of the GR agonist corticosterone (CORT) ranging from 3 to 3000 μg/kg, resulting in clear differences in the GR-binding profile to individual GBS. Two groups of GBS could be distinguished: a low-CORT group that displayed GR binding across the full range of CORT concentrations, and a second high-CORT group that displayed significant GR binding only after administering the highest concentration of CORT. All validated GBS, in both the low-CORT and high-CORT groups, displayed mineralocorticoid receptor binding, which remained relatively constant from 30 μg/kg CORT upward. Motif analysis revealed that almost all GBS contained a glucocorticoid response element resembling the consensus motif in literature. In addition, motifs corresponding with new potential GR-interacting proteins were identified, such as zinc finger and BTB domain containing 3 (Zbtb3) and CUP (CG11181 gene product from transcript CG11181-RB), which may be involved in GR-dependent transactivation and transrepression, respectively. In conclusion, our results highlight the existence of 2 populations of GBS in the rat hippocampal genome.
Collapse
Affiliation(s)
- J Annelies E Polman
- Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | | | | |
Collapse
|
9
|
Jami A, Gadi J, Lee MJ, Kim EJ, Lee MJ, Jung HS, Kim HH, Lim SK. Pax6 expressed in osteocytes inhibits canonical Wnt signaling. Mol Cells 2013; 35:305-12. [PMID: 23529217 PMCID: PMC3887889 DOI: 10.1007/s10059-013-2310-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 02/22/2013] [Accepted: 02/22/2013] [Indexed: 01/10/2023] Open
Abstract
The transcription factor Pax6, which belongs to the paired box-containing gene family, regulates developmental processes, especially in the eyes, central nervous tissues and craniofacial structures. However, the role of Pax6 in bone has never been studied exclusively. Here we report that Pax6 is expressed at both the mRNA and protein level in the calvaria and long bones of adult mice as well as osteocyte-like MLOY4 cells and suppresses the canonical Wnt signaling pathway. Moreover, the expression levels of Pax6 were much higher in the calvaria than the long bones, and Pax6 was also expressed at E16 to E18 in both the calvaria and long bones. Knockdown of Pax6 in MLOY4 cells did not affect cell proliferation or survival; however, the expression of Sost, an osteocyte marker gene, was significantly decreased. In addition, the overexpression of Pax6 suppressed the canonical Wnt signaling pathway by enhancing the expression of Sost. Furthermore, we also demonstrated that Pax6 binds to the Sost promoter and that stimulation of Sost transcription by Pax6 was dependent on a specific Pax6-binding sequence within the promoter. In conclusion, the results of the present study suggest that Pax6 is expressed in bone and may play an important role in osteocyte differentiation by controlling canonical Wnt signaling.
Collapse
Affiliation(s)
- Ajita Jami
- Division of Endocrinology, Department of Internal Medicine, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752,
Korea
| | - Jogeswar Gadi
- Division of Endocrinology, Department of Internal Medicine, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752,
Korea
| | - Min Jung Lee
- Division of Anatomy and Developmental Biology, Department of Oral Biology, Brain Korea 21 Project, Oral Science Research Center, College of Dentistry, Yonsei Center of Biotechnology, Yonsei University, Seoul 120-752,
Korea
| | - Eun Jin Kim
- Institute of Bio-Medical Sciences, Yonsei University, Seoul 120-752,
Korea
| | - Mi Jeong Lee
- Division of Endocrinology, Department of Internal Medicine, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752,
Korea
| | - Han-Sung Jung
- Division of Anatomy and Developmental Biology, Department of Oral Biology, Brain Korea 21 Project, Oral Science Research Center, College of Dentistry, Yonsei Center of Biotechnology, Yonsei University, Seoul 120-752,
Korea
| | - Hong-Hee Kim
- Department of Cell and Developmental Biology, Brain Korea 21 Program and Dental Research Institute, Seoul National University, Seoul 110-749,
Korea
| | - Sung-Kil Lim
- Division of Endocrinology, Department of Internal Medicine, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752,
Korea
- Institute of Bio-Medical Sciences, Yonsei University, Seoul 120-752,
Korea
| |
Collapse
|